Evidence map›Paper›PMID 27267961›Full record

Observational studyBMC urology2016

An observational study of the use of beclomethasone dipropionate suppositories in the treatment of lower urinary tract inflammation in men.

Giorgio Bozzini, Marco Provenzano, Nicolò Buffi, Mauro Seveso, Giovanni Lughezzani, Giorgio Guazzoni, Alberto Mandressi, Gianluigi Taverna

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in BMC urology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Giorgio BozziniDepartmentt of Urology, Humanitas Mater Domini, Via Gerenzano 2, I - 21053, Castellanza, Varese, Italy. gioboz@yahoo.it.
Marco ProvenzanoHumanitas University, Milan, Italy.
Nicolò BuffiDepartment of Urology, Humanitas Research Hospital, Milan, Italy.
Mauro SevesoDepartmentt of Urology, Humanitas Mater Domini, Via Gerenzano 2, I - 21053, Castellanza, Varese, Italy.
Giovanni LughezzaniDepartment of Urology, Humanitas Research Hospital, Milan, Italy.
Giorgio GuazzoniHumanitas University, Milan, Italy.
Alberto MandressiDepartmentt of Urology, Humanitas Mater Domini, Via Gerenzano 2, I - 21053, Castellanza, Varese, Italy.
Gianluigi TavernaDepartmentt of Urology, Humanitas Mater Domini, Via Gerenzano 2, I - 21053, Castellanza, Varese, Italy.
Humanitas Mater Domini · ITIRCCS Humanitas Research Hospital · ITHumanitas University · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNonbacterial prostatitis, together with chronic pelvic pain syndrome, accounts for 90-95 % of prostatitis cases. Anti-inflammatory medications are commonly used to reduce storage/inflammatory symptoms that can deteriorate quality of life. The purpose of this study was to observe the efficacy and safety of beclomethasone dipropionate rectal suppositories (Topster®) in inflammations of the lower urinary tract in men.

methodsPatients underwent diagnostic and therapeutic protocols according to current evidence-based practice. Efficacy assessments: voiding parameters, perineal pain, International Prostate Symptom Score (IPSS), digital rectal examination (DRE). Adverse events and patient compliance were recorded throughout the study.

resultsOne hundred eighty patients were enrolled, mean age 52 ± 14.97. Most frequent diagnosis: nonbacterial prostatitis (85 %). All patients completed visits 1 and 2. All patients were treated with beclomethasone dipropionate (BDP) suppositories, 136/180 also with Serenoa repens (SR) extract. Antibiotics were rarely required. 162/180 patients presented clinically significant improvements and terminated treatment. Mean change vs. baseline in voiding frequency: -3.55 ± 2.70 n/day in patients taking only BDP and -3.68 ± 2.81 n/day in those taking both BDP and SR (P<.0001 in both groups). Uroflowmetry improved significantly; change from baseline 3.26 ± 5.35 ml/s in BDP only group and 5.61 ± 7.32 ml/s in BDP + SR group (P = 0.0002 for BDP, P<.0001 for BDP + SR). Urine stream normal in 35 % of patients at visit 1 and 57.22 % of patients at visit 2. Mean change in perineal pain, on 0-10 VAS, -0.66 ± 2.24 for BDP only group (P = 0.0699) and -1.37 ± 2.40 for BDP + SR group (P<.0001). IPSS increased at visit 2. No adverse events were reported. For all parameters, none of the comparisons between groups was found to be statistically significant.

conclusionThis study confirmed the drug's good safety profile. We also observed an improvement in the main storage symptoms and clinical findings associated with lower urinary tract inflammation in patients treated with beclomethasone dipropionate suppositories.

Indexed as

AdultAgedAged, 80 and overAnti-Inflammatory AgentsBeclomethasoneHumansLower Urinary Tract SymptomsMaleMiddle AgedPelvic PainProstatitisSuppositoriesTreatment OutcomeYoung AdultAnti-Inflammatory AgentsBeclomethasoneSuppositoriesBeclomethasone dipropionateLower urinary tract inflammationNonbacterial prostatitis

Identifiers

PMID27267961
PMCPMC4897870
OpenAlexW2413871915

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.